Answers are grounded in this paper and cite their sources.
Our findings present a distinct molecular class of pediatric-type malignant gliomas largely overlapping with the recently reported bithalamic gliomas characterized by EGFR alteration, but additionally showing a broader spectrum of EGFR alterations and tumor localization. Global H3K27me3 loss in this group appears to be mediated by either H3 K27 mutation or EZHIP overexpression. EGFR inhibition may represent a potential therapeutic strategy in these highly aggressive gliomas.
No takes yet. Share an insight, caveat, or question.
Sievers et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: